Fundamental dimension Equity attribute | BQSTPeer $0.250.00% Cap $7.47MP/E -8.7x QuantScore36/100 | CHHELeader $0.00010.00% Cap $6.55KP/E -0.0x QuantScore46/100 | ECGSPeer $0.040.00% Cap $2.28MP/E -1.6x QuantScore25/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
64/100 |
64/100 |
59/100 |
Valuation Multiples, PEG & DCF upside | 0/100 | 33/100 | 0/100 |
Health Piotroski, Altman Z, leverage & liquidity | 27/100 | 60/100 | 20/100 |
Growth Revenue / earnings growth & margins | 55/100 | 25/100 | 20/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | -8.7x | -0.0x | -1.6x |
Forward P/E (next FY) | — | — | — |
EV / EBITDA (TTM) | -13.2x | -4.4x | -7.3x |
Price / Sales | 40.5x | 0.1x | — |
Price / Free Cash Flow | -26.6x | -0.0x | -0.4x |
PEG ratio | -0.39 | 0.00 | -0.07 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 4 / 9 | 1 / 9 | 0 / 9 |
Altman Z-Score | -5464.29 (Distress) | 9.70 (Safe) | -47.20 (Distress) |
Total debt / equity | -0.35 | 0.13 | -0.77 |
Quick ratio | 0.0x | 6.9x | 0.0x |
Interest coverage | -9.1x | -3194.1x | -112.3x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | +23.7% | +41689.9% | — |
Net income growth YoY | -15.8% | -15.5% | +14.5% |
Gross margin (TTM) | 113.0% | 0.2% | 0.0% |
Operating margin (FY) | -469.3% | -1651.7% | — |
FCF margin (FY) | -168.2% | -37885.7% | — |
5. Trailing price performancePrice change over period |
1M return | +273.1% | +0.0% | -11.1% |
3M return | +278.8% | +0.0% | -6.8% |
6M return | +267.6% | +0.0% | -70.6% |
Year to date | -51.1% | +0.0% | -68.6% |
1Y return | -75.0% | 0.0% | -90.0% |
3Y return | +1001.3% | -100.0% | -90.5% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $-0.0063 -102.5% premium | $-0.0692 -69273.5% premium | $-0.0701 -275.3% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |